Chengdu Medical College, Chengdu, China.
Chengdu Medical College of Basic Medical Sciences, Chengdu, China.
Front Cell Infect Microbiol. 2022 Nov 24;12:1044770. doi: 10.3389/fcimb.2022.1044770. eCollection 2022.
2019 Coronavirus disease (COVID-19) is endangering health of populations worldwide. Latest research has proved that (LHQW) can reduce tissue damage caused by inflammatory reactions and relieve patients' clinical symptoms. However, the mechanism of LHQW treats COVID-19 is currently lacking. Therefore, we employed computer simulations to investigate the mechanism of LHQW treats COVID-19 by modulating inflammatory response.
We employed bioinformatics to screen active ingredients in LHQW and intersection gene targets. PPI, GO and KEGG was used to analyze relationship of intersection gene targets. Molecular dynamics simulations validated the binding stability of active ingredients and target proteins. Binding free energy, radius of gyration and the solvent accessible surface area were analyzed by supercomputer platform.
COVID-19 had 4628 gene targets, LHQW had 1409 gene targets, intersection gene targets were 415. Bioinformatics analysis showed that intersection targets were closely related to inflammation and immunomodulatory. Molecular docking suggested that active ingredients (including: licopyranocoumarin, Glycyrol and 3-3-Oxopropanoic acid) in LHQW played a role in treating COVID-19 by acting on CSF2, CXCL8, CCR5, NLRP3, IFNG and TNF. Molecular dynamics was used to prove the binding stability of active ingredients and protein targets.
The mechanism of active ingredients in LHQW treats COVID-19 was investigated by computer simulations. We found that active ingredients in LHQW not only reduce cell damage and tissue destruction by inhibiting the inflammatory response through CSF2, CXCL8, CCR5 and IFNG, but also regulate cell survival and growth through NLRP3 and TNF thereby reducing apoptosis.
2019 年冠状病毒病(COVID-19)正在威胁着全球人口的健康。最新研究表明,(LHQW)可以减轻炎症反应引起的组织损伤,缓解患者的临床症状。然而,LHQW 治疗 COVID-19 的机制目前尚不清楚。因此,我们采用计算机模拟的方法,通过调节炎症反应来研究 LHQW 治疗 COVID-19 的作用机制。
我们采用生物信息学方法筛选 LHQW 中的活性成分和交集基因靶点。通过 PPI、GO 和 KEGG 分析交集基因靶点之间的关系。分子动力学模拟验证了活性成分与靶蛋白的结合稳定性。通过超级计算机平台分析结合自由能、回转半径和溶剂可及表面积。
COVID-19 有 4628 个基因靶点,LHQW 有 1409 个基因靶点,交集基因靶点有 415 个。生物信息学分析表明,交集靶点与炎症和免疫调节密切相关。分子对接表明,LHQW 中的活性成分(包括:花椒毒素、甘草醇和 3-3-氧代丙酸)通过作用于 CSF2、CXCL8、CCR5、NLRP3、IFNG 和 TNF 发挥治疗 COVID-19 的作用。分子动力学用于证明活性成分与蛋白质靶标的结合稳定性。
通过计算机模拟研究了 LHQW 中活性成分治疗 COVID-19 的作用机制。我们发现,LHQW 中的活性成分不仅通过抑制 CSF2、CXCL8、CCR5 和 IFNG 抑制炎症反应来减轻细胞损伤和组织破坏,还通过 NLRP3 和 TNF 调节细胞存活和生长,从而减少细胞凋亡。